PLK1 and neoplasm: In this regard, restoration of p53 in tumor cells with loss or mutation of p53 will promote the cytotoxicity of combined Plk1 therapy, prevent genome instability induced by Plk1 inhibitors, and provide an effective strategy for combating relapse and metastasis of cancer (Fig. 3).